Core Viewpoint - The company reported a significant decline in revenue and net profit for the first half of 2025, primarily due to a decrease in the revenue from non-invasive prenatal genetic testing and challenges in the international market [1][5]. Financial Performance - The company's operating revenue for the first half of 2025 was approximately 1.63 billion yuan, a decrease of 12.82% compared to the same period last year [1]. - The net profit attributable to shareholders was approximately 5.78 million yuan, down 68.25% year-on-year [1]. - The net profit after deducting non-recurring gains and losses was approximately -30.49 million yuan, reflecting a drastic decline of 2,610.77% [1]. - The net cash flow from operating activities was -413.84 million yuan, a decrease of 414.23% compared to the previous year [1]. - Basic earnings per share were 0.0139 yuan, down 67.90% year-on-year [1]. Business Segments - Revenue from non-invasive prenatal genetic testing decreased by approximately 35% due to a slight decline in sample volume [5]. - The reproductive health business saw a 15% increase in revenue from genetic testing for hereditary diseases in the clinical diagnosis sector [5]. - The company achieved significant growth in overseas markets, particularly in Latin America, where revenue from non-invasive prenatal genetic testing showed strong momentum [5][6]. - The single-cell sequencing business within the multi-omics segment experienced a notable revenue increase of approximately 110% [5]. Strategic Initiatives - The company is focusing on enhancing its product offerings in high-margin areas to counteract the price decline of basic non-invasive prenatal testing products [5]. - Efforts are being made to expand the sales layout for colorectal cancer detection products in the consumer market [5]. - The introduction of a fully automated local solution for high-throughput pathogen sequencing aims to meet the detection needs of various medical institutions [5].

在全球产业链重构与科技博弈加剧的当下，"自主可控+国产替代"正演化成资本市场最清晰的价值锚点。在这轮时代大考中， 真正具备底层创新能力的科技企业正显露出穿越周期的韧性。 行业承压寻突破，结构韧性谋新篇 在行业整体承压的背景下，华大基因2024年度报告呈现出独特的结构韧性。在逆周期环境中仍勾勒出清晰的发展脉络。 在生育健康领域，尽管新生儿出生率持续走低，华大基因却凭借其在该领域的深厚积累与前瞻布局，展现出相对稳健的态 势。其中新生儿遗传病基因筛查业务营业收入同比增长约47.38%；辅助疾病临床诊断方向的遗传病基因检测系列业务营业收 入同比增长约53.13%。 公司不仅构建了覆盖婚前、孕前、孕期、新生儿及儿童全周期的出生缺陷三级防控体系，还通过精准定位民生需求，成功承 接了多地如广州、杭州等地推广孕妇外周血胎儿游离DNA产前筛查及出生缺陷检测服务项目，有效促进了出生缺陷的预防与 减少，也进一步提升了其业务渗透率。 市场前景上来看，公司积极持续拓展产品布局，优化成本以及国产率，将基因检测从二级预防向一级以及三级预防业务不断 延伸，向外扩展业务边际，在提高市场渗透率的同时向上打开市场空间。 同时，华大基因在肿瘤与慢病 ...